Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CDC25A | P30304 | 6/20 | 0.37 |
| ▸ | CDC25B | P30305 | 6/20 | 0.37 |
| ▸ | CDC25C | P30307 | 5/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021386 | 1.00 | ACHE (0.37) | ACHEBACE1CDC25ACDC25BCDC25C | |
| SCHEMBL4629705 | 1.00 | ACHE (0.37) | ACHEBACE1CDC25ACDC25BCDC25C | |
| SCHEMBL704205 | 0.98 | ACHE (0.34) | ACHEBACE1CDC25ACDC25BCDC25C | |
| Hexanoate SCHEMBL27802806 | 0.86 | SCD (0.51) | CDC25ACDC25BCDC25CGPR84 | |
| SCHEMBL9992284 | 0.81 | FNTA (0.37) | — | |
| SCHEMBL7054062 | 0.80 | CYP1A2 (0.34) | ACHEBACE1CDC25ACDC25BCDC25C | |
| SCHEMBL9264130 | 0.76 | ACHE (0.40) | ACHEBACE1CDC25ACDC25BCDC25C | |
| SCHEMBL8780203 | 0.76 | ACHE (0.40) | ACHEBACE1CDC25ACDC25BCDC25C | |
| SCHEMBL14751591 | 0.75 | GPR84 (0.37) | ACHEBACE1CDC25ACDC25BCDC25C | |
| SCHEMBL11156027 | 0.74 | ACHE (0.37) | ACHEBACE1CDC25ACDC25BCDC25C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478444-B | Efficient catalytic synthesis method of 5-n-octyl-furan-2-one | 耕海生物科技(深圳)有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-114478444-A | Efficient catalytic synthesis method of 5-n-octyl-furan-2-one | 耕海生物科技(深圳)有限公司 | 2022-05-13 | — | — | CN | claimed |
| EP-2167025-B1 | PRESERVATIVE-FREE COMPOSITIONS COMPRISING CINNAMIC OR ANISIC ACID AND A BENZALDEHYDE (DERIVATIVE) | GIVAUDAN SA (CH) | 2018-08-08 | — | — | EP | claimed |
| US-20100183692-A1 | COMPOSITIONS | GIVAUDAN SA (CH) | 2010-07-22 | — | — | US | claimed |
| EP-2167025-A2 | PRESERVATIVE-FREE COMPOSITIONS COMPRISING CINNAMIC OR ANISIC ACID AND A BENZALDEHYDE (DERIVATIVE) | Givaudan SA (CH) | 2010-03-31 | — | — | EP | claimed |
| WO-2009000097-A2 | PRESERVATIVE-FREE COMPOSITIONS COMPRISING CINNAMIC OR ANISIC ACID AND A BENZALDEHYDE (DERIVATIVE) | GIVAUDAN SA (CH) | 2008-12-31 | — | — | WO | claimed |
| US-20080311054-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-12-18 | — | — | US | claimed |
| US-20080247966-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-10-09 | — | — | US | claimed |
| EP-1937365-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-07-02 | — | — | EP | claimed |
| EP-1919566-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-05-14 | — | — | EP | claimed |
| WO-2007025401-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
| WO-2007025402-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
| CN-114478444-B | Efficient catalytic synthesis method of 5-n-octyl-furan-2-one | 耕海生物科技(深圳)有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-114478444-B | Efficient catalytic synthesis method of 5-n-octyl-furan-2-one | 耕海生物科技(深圳)有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-114478444-A | Efficient catalytic synthesis method of 5-n-octyl-furan-2-one | 耕海生物科技(深圳)有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114478444-A | Efficient catalytic synthesis method of 5-n-octyl-furan-2-one | 耕海生物科技(深圳)有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-1937365-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-07-02 | — | — | EP | disclosed |
| EP-1919566-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007025402-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007025401-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311054-A1 | Compositions and Methods to Counteract Oral Malodour | TAS2R60, TAS2R40, LPO | ACHE 134/4885BACE1 2488/4885CDC25A 3869/4885 |
| US-20100183692-A1 | COMPOSITIONS | NISCH, CUTA, C9 | ACHE 2051/4885BACE1 711/4885CDC25A 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.